Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI104668

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2016-2027
Base Year	2019
Forecast Period	2020-2027
Historical Period	2016-2018
Unit	Value (USD million)
Segmentation	By Drug Class Prophylaxis Palivizumab Nirsevimab MK-1654 Other Prophylaxis Treatment Ribavirin JNJ 53718678 Enanta EDP-938 ASCENIV
	By End User Hospital Pharmacy Retail Pharmacy Online Pharmacy
	By Geography North America (U.S. and Canada) Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)